Recognizing these developments, the 2024 KDIGO CKD guideline recommends initiating SGLT2 inhibitors in CKD patients (with or without T2D) with an eGFR ≥ 20 mL/min, cementing their role as a mainstay therapy alongside RAAS blockade [7]. Here, SLC5A2 is linked to chronic kidney disease.